腺苷-肌苷（A-to-I）RNA编辑是核苷酸多样性的主要源头，对癌症进展和治疗反应具有重要的机制意义。然而，它在单个细胞分辨率下的活性和普遍性尚未得到系统性的确定。陈等人通过对一个公共的肺腺癌单细胞转录组数据集进行深度分析，揭示了单个癌细胞中广泛的A-to-I RNA编辑事件。与其他细胞类型相比富集在癌细胞中的编辑有可能抑制先天免疫反应，并预测病人在接受靶向治疗时的治疗反应和预后。详见陈等人的相关文章，第374页。© 2023美国癌症研究协会。

Adenosine-to-inosine (A-to-I) RNA editing is a major source of nucleotide diversification that has significant mechanistic implications in cancer progression and treatment response. However, its activity and prevalence have not yet been systematically determined at a single-cell resolution. Chan and colleagues revealed widespread A-to-I RNA editing events in single cancer cells through an in-depth analysis of a public lung adenocarcinoma single-cell transcriptome dataset. Edits significantly enriched in cancer cells compared to other cell types have the potential to inhibit innate immune response and to predict poor therapeutic response and prognosis in patients treated with targeted therapies. See related article by Chan et al., p. 374.©2023 American Association for Cancer Research.